

Nanowarming: Using Molecular Nanotechnology to Make Organ Banking Possible

A quantitative framework, and translational roadmap

Andrew Skow

Abstract

The shortage of transplantable organs is partly a shortage of time. Hearts, livers, lungs, and kidneys begin accumulating ischemic injury as soon as circulation stops, forcing allocation, transport, testing, and surgery into a narrow window. Vitrification offers a route to deep cryogenic storage without destructive ice, but it creates a second problem: a vitrified organ must be rewarmed fast enough to suppress devitrification and uniformly enough to prevent fracture. Nanowarming addresses that bottleneck by perfusing magnetic iron oxide nanoparticles through the organ vasculature and exciting them with an alternating magnetic field, converting distributed nanoscale losses into volumetric heat. The evidence has advanced from artery and valve recovery, to vitrified rat hearts, kidneys, and livers, to life sustaining transplantation of rat kidneys stored for as long as 100 days. Human scale physics has also moved forward. In 2025, three liter cryoprotective agent volumes were vitrified and two liter volumes were nanowarmed at about 88 degrees Celsius per minute with temperature differences below about 5 degrees Celsius. In 2026, ferumoxytol was repurposed for rat kidney nanowarming, and application specific toxicology showed a wide exposure margin between reported organ residuals and doses producing acute toxicity in rats. These results make organ banking physically credible, but not yet clinically demonstrated. This paper identifies the remaining coupled barriers, including cryoprotectant toxicity, vascular delivery heterogeneity, field uniformity, thermomechanical stress, nanoparticle manufacture and washout, organ specific functional injury, and the absence of large animal transplant validation. It also introduces the weakest voxel principle, a proposed Organ Banking Margin, particle gradient compensation, and a closed loop digital twin strategy. Together, these concepts turn nanowarming from a single heating method into a measurable systems engineering program for human organ banking.

Keywords: *nanowarming, organ banking, vitrification, iron oxide nanoparticles, cryopreservation, transplantation, radiofrequency heating, magnetic particle imaging*

1. Introduction, the organ shortage is also a time shortage

Transplantation is often described as a problem of organ supply, yet every donated organ is also governed by a rapidly expiring clock. Static cold storage slows metabolism but does not stop it. Ischemic injury, endothelial dysfunction, inflammation, mitochondrial damage, and reperfusion injury accumulate as transport and allocation continue. The result is a system in which geographical distance and operating room timing can determine whether an otherwise useful organ is transplanted. Organ banking would change that logic. A graft could be preserved, typed, evaluated, transported, matched, and scheduled rather than raced against a few hours of deterioration (Giwa et al., 2017; Lewis et al., 2016).

Machine perfusion, supercooling, and partial freezing are important extensions of the clinical window. Human livers have been maintained in a supercooled state for about 27 hours, and partial freezing extended rat liver preservation several fold (de Vries et al., 2019; Tessier et al., 2022). These approaches are valuable bridges, especially when days rather than months are needed. They do not provide the near arrest of molecular motion expected below the glass transition. Long duration banking instead requires a reversible transition into a stable, ice free solid state.

Vitrification is that transition. Cryoprotective agents reduce the tendency of water to crystallize and allow biological material to become an amorphous glass during cooling. The method has long been successful for cells, embryos, and small tissues. Whole organs are more difficult because heat and solute must traverse centimeters of heterogeneous, vascularized tissue. The decisive obstacle is often not cooling but rewarming. Critical warming rates can exceed critical cooling rates by one or more orders of magnitude, and heating from the surface creates a dangerous tradeoff. Slow centers can crystallize while fast surfaces expand, generating gradients and fracture (Fahy et al., 1984; Fahy et al., 2004; Rabin et al., 2006).

Nanowarming changes the geometry of heat delivery. Instead of forcing heat from the surface toward the center, it places nanoscale magnetic heat sources throughout the vascular space and activates them with a penetrating alternating magnetic field. The organ is therefore warmed from within. The idea is simple, but clinical success requires coordinated control of molecular formulation, nanoparticle chemistry, perfusion, cryogenic thermodynamics, electromagnetic fields, structural mechanics, washout, and transplant biology. Nanowarming is best understood as a complete systems problem, not as a coil attached to a frozen organ.

2. Scope, terminology, and analytical method

This article is a critical narrative review and engineering perspective. It prioritizes peer reviewed primary studies that directly address magnetic nanoparticle synthesis, organ perfusion, vitrification, volumetric rewarming, tissue recovery, transplantation, scale, manufacturing, and biosafety. Evidence available through August 2026 is organized by the biological strength of the endpoint, with physical vitrification below ex vivo function, and ex vivo function below survival dependent transplantation. The paper does not treat physical success in a cryoprotective solution as equivalent to successful preservation of a living human organ.

The term molecular nanotechnology is used here in its experimentally established biomedical sense: the deliberate design of nanoscale materials and molecular interfaces to control heat generation, colloidal stability, transport, imaging, and biological compatibility. It does not imply autonomous molecular machines. Iron oxide cores, silica or polymer coatings, cryoprotective molecules, ice controlling polymers, and nanoscale imaging signals form an engineered molecular system whose collective behavior appears at organ scale (Murray and Gibson, 2022; Gao et al., 2020).

3. Why rewarming, not storage, is the central physical problem

3.1 Ice avoidance creates a narrow thermal corridor

An organ loaded with a vitrification solution must cool faster than the solution and tissue specific critical cooling rate. During warming it must exceed the critical warming rate through the temperature interval in which ice nuclei can grow. If warming is too slow, devitrification produces ice. If warming is spatially uneven, differential thermal expansion creates mechanical stress and cracking. A protocol

can therefore fail even when its average warming rate looks excellent. The relevant quantity is the coldest and slowest local region during the crystallization danger interval, together with the largest stress generating temperature difference in the glassy interval.

Cryoprotective agents lower the required cooling and warming rates, but their protection is purchased with osmotic and chemical toxicity. Stepwise or continuously controlled loading reduces abrupt cell volume changes, while low temperature exposure slows toxic reactions. Even so, the concentration required for reliable vitrification can injure endothelium, tubules, hepatocytes, bile ducts, and other compartments differently. Research on vitrification solutions has repeatedly shown that total molarity alone does not predict toxicity, which means formulation, temperature, exposure time, and organ specific transport must be optimized together (Fahy et al., 2004; Guan et al., 2012; Murray and Gibson, 2022).

3.2 Volumetric magnetic heating

In nanowarming, iron oxide nanoparticles dissipate energy when driven by an alternating magnetic field. Depending on particle size, anisotropy, aggregation state, field strength, frequency, and temperature, heat arises from magnetic relaxation and hysteretic losses. The useful engineering quantity is the iron normalized specific absorption rate, SAR_{Fe}. If C_{Fe} is the local iron concentration, the local nanoparticle heat source is approximated by:

$$q'''_{np}(x, t) = C_{Fe}(x) \times SAR_{Fe} [H(x, t), f, T(x, t)]$$

The organ temperature field follows the heat equation:

$$\rho c_p \partial T / \partial t = \nabla \cdot (k \nabla T) + q'''_{np} + q'''_{eddy}$$

Here, density, heat capacity, and thermal conductivity are represented by ρ , c_p , and k . The desired nanoparticle source is q'''_{np} . The term q'''_{eddy} represents unintended direct heating caused by induced currents. At the frequencies used for nanowarming, magnetic fields can penetrate organ scale samples with little attenuation, but the field still must be spatially uniform and the cryoprotective agent electrical properties must be known. Temperature dependent particle heating and off target electromagnetic heating therefore belong in the control model, not in a post hoc explanation (Gangwar et al., 2025a; Gangwar et al., 2025b).

Table 1. Coupled constraints in vitrification and nanowarming.

Constraint	Failure mechanism	Evidence required for control
Cryoprotectant loading	Underloading permits ice, overexposure causes osmotic and chemical injury.	Three dimensional concentration mapping, pressure and flow records, tissue specific toxicity.
Nanoparticle distribution	Sparse regions warm too slowly, aggregates can obstruct microvessels and alter local heating.	Spatial particle map, colloidal stability, vascular resistance, histology.
Cooling	The center cools below the required rate or the glass fractures from thermal stress.	Local cooling rate above the critical rate, verified ice absence, bounded temperature difference.

Constraint	Failure mechanism	Evidence required for control
Storage	Temperature excursions, glass aging, and brittleness can change recovery requirements.	Continuous temperature history and duration studies, not a single endpoint measurement.
Rewarming	Devitrification occurs in cold pockets, while gradients create cracking or local overheating.	Local warming rate margin, stress model, multipoint thermometry, ice sensitive imaging.
Washout	Residual cryoprotectants or nanoparticles may be toxic, inflammatory, or obstructive.	Mass balance, regional residual assay, effluent kinetics, toxicology based release limits.
Biological recovery	An intact looking organ can still have endothelial, epithelial, mitochondrial, electrical, or biliary failure.	Normothermic perfusion and survival dependent transplantation with organ specific endpoints.

4. Experimental evidence, from tissues to functioning grafts

4.1 The founding tissue scale demonstration

Manuchehrabadi and colleagues established the modern nanowarming platform by dispersing silica coated iron oxide nanoparticles in vitrification solutions and using radiofrequency excitation to rewarm systems ranging from small volumes to tens of milliliters. Porcine arteries and heart valves showed improved viability and mechanical recovery compared with convective warming. The crucial conceptual advance was simultaneous speed and uniformity, because the field penetrated the sample while the nanoparticles acted as distributed absorbers (Manuchehrabadi et al., 2017). This work did not prove organ transplantation, but it removed the assumption that large vitrified tissues must always be rewarmed from their boundaries.

4.2 Nanoparticle chemistry became an organ technology

Commercial ferrofluids can aggregate in concentrated cryoprotective solutions, and aggregation is unacceptable inside an organ microcirculation. Gao and colleagues developed a silica coated iron oxide particle that could be synthesized in about one day at up to 1.4 grams of iron per batch, remained stable in cryoprotective agent, heated efficiently, and could be loaded into and washed from rat kidneys (Gao et al., 2020). Chiu Lam and colleagues separately formulated polymer coated superparamagnetic particles that remained colloidally stable before and after vitrification, produced warming rates as high as 321 degrees Celsius per minute in relevant solutions, and were quantified in rat hearts by magnetic particle imaging after loading and washout (Chiu Lam et al., 2021). These studies made surface chemistry, purification, and measurement central to nanowarming rather than auxiliary details.

Heating efficiency is not the only design target. Particles must balance high SAR_{Fe}, small and stable hydrodynamic size, low interaction with proteins and vessel walls, reproducible manufacture, and efficient removal. Engineered magnetic nanoclusters can increase heating efficiency, but higher magnetic loss is useful only if the formulation remains perfusable and biocompatible (Ye et al., 2024). For organ banking, the best nanoparticle is therefore not the hottest particle in a vial. It is the particle that produces a predictable spatial heat source after organ loading and can then be removed to a prespecified safety limit.

4.3 Heart, kidney, liver, and cartilage models

Rat heart studies demonstrated successful vascular loading, ice free cooling, nanowarming without cracking, preserved histologic and endothelial integrity, and limited electrical activity after recovery. These were physical and ex vivo biological achievements, not demonstrations of a heart capable of supporting circulation after transplantation (Gao et al., 2022).

Thermomechanical models of rat and human hearts further showed that container geometry, surrounding solution, and nonuniform nanoparticle concentration can shift stress patterns even when average warming remains rapid (Joshi et al., 2022; Joshi et al., 2023).

Rat kidney work progressed further. Sharma and colleagues achieved mean nanowarming near 63.7 degrees Celsius per minute, avoided ice and cracking, and preserved histology and endothelial structure more effectively than convective warming (Sharma et al., 2021). Han and colleagues then replaced the more toxic VS55 formulation with VMP, optimized loading by transport modeling, and nanowarmed kidneys at 72.0 plus or minus 8.0 degrees Celsius per minute, above the measured tissue critical warming rate of about 50 degrees Celsius per minute.

Kidneys were stored at minus 150 degrees Celsius for 1 to 100 days. In five syngeneic recipients whose native kidneys were removed, every nanowarmed graft supported survival through the 30 day study. Renal dysfunction was evident early, but creatinine reached the control range by day 23 and terminal estimated filtration was not statistically different from fresh graft controls (Han et al., 2023a). This is the strongest biological evidence for organ nanowarming to date. It remains a small rodent study, and the cold stored comparison involved only one 60 hour kidney, so it is a foundation for replication and scale rather than a clinical endpoint.

The liver exposes a different weakness. Rat livers were perfused with ethylene glycol and sucrose plus silica coated particles, vitrified, and rewarmed at about 61 degrees Celsius per minute while keeping the surface to interior temperature difference below 15 degrees Celsius. Architecture, vascular endothelium, bile production, and hepatocyte uptake were preserved, but liver enzymes increased and indocyanine green excretion was impaired. Portal vein only loading may also have underprotected the arterial and biliary compartments (Sharma et al., 2023). The experiment shows that successful temperature control does not guarantee uniform biological protection.

Large porcine osteochondral allografts provide an instructive avascular test. Nanowarming of approximately 9 milliliters of tissue in about 39 milliliters total volume raised the solution warming rate to 76.8 degrees Celsius per minute compared with 4.8 degrees Celsius per minute for convection. Cell metabolic activity and viability improved, but deep cartilage remained less protected because nanoparticles did not uniformly enter the avascular tissue.

The depth gradient linked biological recovery to heat source placement, a direct warning against relying on bulk averages (Chen et al., 2023).

Table 2. Major experimental milestones and the claim each result can support.

Study	What was demonstrated	What remains unproven
Manuchehrabadi et al., 2017	Rapid, uniform rewarming of vitrified systems and recovery of porcine arteries and heart valves.	Whole organ function and transplantation.
Gao et al., 2020	Scalable silica coated particle synthesis, CPA stability, kidney loading and washout.	Recovered organ function after vitrification.
Chiu Lam et al., 2021	Stable magnetic CPA, whole rat heart loading, one week cryostorage, nanowarming, and MPI washout measurement.	Life supporting cardiac function.
Sharma et al., 2021	Rat kidney vitrification and nanowarming with preserved architecture and endothelial integrity.	Transplant survival in that study.
Gao et al., 2022	Rat heart vitrification, uniform nanowarming, histology, and limited electrical activity.	Hemodynamic recovery and transplant survival.
Sharma et al., 2023	Rat liver vitrification, nanowarming, intact architecture, bile production, and ex vivo function.	Normal biliary function and transplantation.
Han et al., 2023a	Rat kidneys banked for up to 100 days, nanowarmed, transplanted, and life sustaining for 30 days.	Large animal and human scale biological success.
Chen et al., 2023	Improved recovery of large porcine cartilage with a measured depth dependent response.	Uniform recovery of deep avascular tissue.
Gangwar et al., 2025a	Three liter vitrification, two liter uniform nanowarming, and physical vitrification of a porcine liver.	Rewarming and functional recovery of a human size organ.
Feng et al., 2026	Ferumoxylol enabled uniform rat kidney nanowarming near 79.9 degrees Celsius per minute with preserved viability.	Washout limits and transplant outcomes for this formulation.

4.4 Human scale physics has crossed an important threshold

The central scale objection weakened substantially in 2025. Gangwar and colleagues vitrified cryoprotective agent volumes from 0.5 to 3 liters. M22 vitrified successfully at 3 liters, while VS55 failed at the tested volumes. Porcine livers with total volumes near the human kidney and heart range were perfused and physically vitrified, although those livers were not nanowarmed. A newly developed 120 kilowatt coil generated a field uniform within about 5 percent over the working region. One liter samples containing about 10.7 milligrams iron per milliliter reached 0 degrees Celsius in about one minute at roughly 172 degrees Celsius per minute. Two liter samples containing about 4.6 milligrams iron per milliliter warmed at about 88 degrees Celsius per minute, with measured temperature differences below about 5 degrees Celsius (Gangwar et al., 2025a).

These are not transplantable organs, but they are not trivial surrogates. They show that liter scale vitrification and rapid, spatially controlled magnetic rewarming are physically achievable. They also shift the predicted bottleneck. Because nanowarming rate is primarily controlled by local particle concentration and field rather than total sample volume, convective cooling, perfusion uniformity, and biological tolerance may become more limiting than the nominal power of the rewarming system at human scale.

An organ banking chain is only as strong as its weakest step




Figure 1. The nanowarming organ banking chain. Each step imposes a separate physical or biological release criterion. A rapid rewarming rate cannot compensate for incomplete cryoprotectant loading, particle maldistribution, failed washout, or inadequate graft function.

5. The translational barriers that now matter most

5.1 Cryoprotectant toxicity and heterogeneous transport

The dominant biological injury in the successful rat kidney program was traced to cryoprotective agent exposure rather than to the physical nanowarming step. That finding is strategically important because it separates the heating problem from the formulation problem without making them independent. Loading must deliver enough protection to every compartment before cooling, yet exposure must remain below organ specific toxicity. Mass transport models can design concentration ramps and predict tissue equilibration, as shown in kidney protocol optimization, but models require validation against spatial concentration measurements and cellular endpoints (Han et al., 2023b).

Molecular cryobiology offers several ways to widen this window. Mixed penetrating cryoprotectants can distribute toxicity across compounds, nonpenetrating sugars can stabilize membranes and control osmotic behavior, and ice recrystallization inhibitors can reduce crystal growth without simply increasing total permeating solute. Polymer chemistry, small molecule screening, and data guided discovery are rapidly expanding this design space (Murray and Gibson, 2022; Warren et al., 2024). Every additive must nevertheless be screened with the nanoparticle formulation because salts, polymers, and protein interactions can change aggregation, SARFe, viscosity, glass stability, and electrical loss.

5.2 Particle distribution, stability, and manufacturing

Capillary spacing is favorable for transferring heat from vascular nanoparticles into surrounding tissue, but only if particles reach the capillary bed. Vascular disease, spasm, thrombosis, air, edema, and anatomical dead zones can create particle poor regions. Aggregation can simultaneously reduce heating, impede washout, and injure the microcirculation. Preconditioning the vascular bed, controlling pressure and flow, measuring resistance, and imaging particle distribution should therefore be part of a single loading protocol.

Manufacturing is moving toward the needed scale. Oziri and colleagues used tangential flow filtration to purify 0.72 grams of silica coated particles in 2.5 hours, compared with a multiday ultracentrifugation workflow. The product remained stable in cryoprotective solutions for more than seven months, retained a SARFe near 360 watts per gram iron under the tested conditions, produced low residual kidney iron after unloading, and was used in recovered kidney transplantation experiments. The same authors estimate that a human kidney could require about 500 milligrams of iron at a target vascular concentration of 10 milligrams per milliliter (Oziri et al., 2025). This converts nanoparticle production from a laboratory detail into a defined biomanufacturing demand.

5.3 Washout and biosafety

Nanowarming is performed ex vivo, and the intended clinical product is an organ from which both particles and cryoprotectants have been removed. Safety must therefore be tied to actual residual exposure, not merely to the concentration used during warming. Magnetic particle imaging, magnetic resonance methods, elemental assays, microcomputed tomography at higher concentrations, and longitudinal detection electron paramagnetic resonance can provide complementary measures of particle amount and location (Chiu Lam et al., 2021; Kantesaria et al., 2024). A whole organ average is insufficient if particles remain concentrated in a few microvascular beds.

The first application specific in vivo toxicology study adds important context. Silica coated particles had a transmission electron microscopy size near 50 nanometers, a hydrodynamic diameter near 86 nanometers, and a zeta potential near minus 41 millivolts. Rats received 5, 12, or 20 milligrams iron per kilogram intravenously. Doses at or below 12 milligrams per kilogram were tolerated in the reported assessment, whereas 20 milligrams per kilogram produced acute hematologic, renal, hepatic, and immune changes. The administered doses were six to seven orders of magnitude above the estimated systemic exposure derived from the highest reported residual iron after nanowarming, about 3.36 nanograms iron per kilogram (Oziri et al., 2026). This is reassuring but not definitive. A bolus injection does not reproduce gradual release from a transplanted organ, protein corona formation, local vascular retention, thrombogenicity, complement activation, or chronic recipient immunosuppression.

Ferumoxytol provides a second translational route. In 2026, an existing clinical iron oxide formulation remained stable in cryoprotective solutions, warmed rat kidneys at about 79.9 degrees Celsius per minute, generated similar thermal histories across cortex, medulla, and hilum, and preserved viability comparable with fresh and static cold stored controls (Feng et al., 2026). Prior clinical use of the material may reduce uncertainty about chemistry and manufacture, but it does not make organ nanowarming an approved use. Heating performance, dose, residual exposure, and organ specific washout still require direct qualification.

5.4 Field scale, eddy heating, and thermomechanical stress

A homogeneous magnetic field does not guarantee a homogeneous temperature field. Local heating is the product of field, frequency, particle response, particle concentration, and temperature. Tissue and cryoprotective agents also contribute boundary losses and unwanted electrical heating. Measurements of VS55, M22, DP6, and their components show that dielectric loss changes nonlinearly with composition, frequency, and temperature. At nanowarming frequencies, estimated eddy heating is small in the cryogenic glass relative to particle heating, but the effect should be calculated for each coil, container, organ, and formulation (Gangwar et al., 2025b).

Thermomechanical injury depends on both temperature gradient and material state. Annealing just above the glass transition can relax stress before final cooling. Slow passage into the brittle glassy region limits renewed gradients. During rewarming, nanoparticle placement in the surrounding cryoprotective agent and within the vasculature can alter the direction and magnitude of principal stress. Modeling should therefore report local tensile stress against a measured failure threshold, not merely maximum temperature difference (Rabin et al., 2006; Joshi et al., 2023).

5.5 Functional proof must match the intended organ

Histologic resemblance is necessary but insufficient. Kidney release testing should include filtration, tubular transport, acid base regulation, concentrating ability, and endocrine recovery. A heart must demonstrate conduction, contractility, coronary integrity, and adequate pressure and output. A liver requires synthetic, metabolic, detoxification, vascular, and biliary function. A lung must maintain barrier integrity, gas exchange, compliance, and low pulmonary vascular resistance. The closer a study moves toward clinical translation, the more the endpoint must shift from staining and short perfusion to survival dependent transplantation.

6. Novel contribution, the weakest voxel principle

The published literature frequently reports mean warming rate, mean iron concentration, or temperatures from a small number of probes. Whole organ failure, however, can begin in a small region. A particle poor voxel can devitrify, a hot voxel can overheat, a steep interface can crack, and a poorly washed vascular branch can seed thrombosis. The proposed weakest voxel principle states that organ banking success is governed by the least protected spatial element that is large enough to propagate structural or biological failure. This principle is consistent with the depth dependent cartilage results and with models showing that realistic particle distributions alter stress (Chen et al., 2023; Joshi et al., 2023).

The practical consequence is that average values should become secondary endpoints. Studies should report spatial percentiles and worst region confidence bounds for cryoprotectant concentration, particle concentration, warming rate, temperature difference, stress, and residual iron. Because sensors are sparse, the full field should be estimated by a validated digital twin constrained by imaging, inlet and outlet data, and fiber optic thermometry.

6.1 A proposed Organ Banking Margin

A cross organ comparison needs a dimensionless framework that preserves the weakest link. This paper proposes five local or system level margins:

$$\begin{aligned} M_{\text{cool}} &= \text{minimum local cooling rate} \div \text{local critical cooling rate} \\ M_{\text{warm}} &= \text{minimum local warming rate} \div \text{local critical warming rate} \\ M_{\text{stress}} &= \text{allowable tensile stress} \div \text{maximum predicted tensile stress} \\ M_{\text{clear}} &= \text{toxicology based residual limit} \div \text{measured residual burden} \\ M_{\text{func}} &= \text{measured organ function} \div \text{prespecified acceptable function} \end{aligned}$$

The proposed Organ Banking Margin, OBM, is the minimum of these five terms:

$$\text{OBM} = \min (M_{\text{cool}}, M_{\text{warm}}, M_{\text{stress}}, M_{\text{clear}}, M_{\text{func}})$$

A margin above 1 means that every specified criterion is met. A margin below 1 identifies the active bottleneck. The OBM is intentionally not an average because averaging can hide a fatal deficit. It is also not yet a validated clinical score. Its value is methodological: it forces investigators to state the critical rate, mechanical limit, residual exposure limit, and functional acceptance threshold before examining the result. Organ specific validation would be required before the number could guide release decisions.




Figure 2. Proposed Organ Banking Margin. The plotted values are illustrative, not experimental. The minimum validated margin, rather than the mean of favorable metrics, determines whether a protocol is ready to advance.

6.2 Designed nonuniformity, particle gradient compensation

Uniform particle concentration is an intuitive target, but it may not produce uniform temperature. Surface regions exchange heat with the container and environment, vessel density varies, and field amplitude can change across the coil. The better target is a designed heat source field. Rearranging the heat equation gives a first approximation for the required local particle concentration:

$$C_{Fe,target}(x) = \{ \rho_{cp} r_{target} - \nabla \cdot [k \nabla T] - q'''_{eddy} \} \div SAR_{Fe}$$

Here, r_{target} is the desired local warming rate. This expression suggests a novel strategy: deliberately compensate for predictable heat losses and vascular heterogeneity by varying particle concentration or surrounding solution concentration, rather than insisting on identical concentration everywhere. The approach must be constrained by vascular safety and washout. Its test is straightforward. At equal total iron mass, an optimized concentration field should reduce the maximum temperature difference and improve the minimum local warming margin compared with a uniform formulation.

6.3 Closed loop nanowarming and the organ digital twin

Current nanowarming is largely open loop: a protocol specifies coil power and duration, while a few probes report temperature. A clinical system should operate as a closed loop controller. Before cooling, imaging would map anatomy, vascular resistance, cryoprotectant distribution, and nanoparticle distribution. A personalized thermal and stress model would then predict the evolving temperature field. During rewarming, fiber optic probes and coil measurements would update the model, and model predictive control would modulate field amplitude or power to keep every estimated region above the critical warming rate while limiting thermal stress. Magnetic particle imaging is particularly valuable because it detects the same material that produces heat. It could serve as a prewarming dosimetry map, while a lower cost regional assay such as longitudinal detection electron paramagnetic resonance could support manufacturing and washout checks (Chiu Lam et al., 2021; Kantesaria et al., 2024). This creates a theranostic loop in the literal sense: the nanoparticle is both the actuator and a measurable tracer.

6.4 A thermal dose ledger for cryoprotectant injury

Cryoprotectant toxicity is often summarized by concentration and exposure time, but temperature changes continuously during loading, cooling, rewarming, and unloading. The relevant biological burden is a temperature weighted exposure history. This paper proposes a thermal dose ledger that integrates organ and compartment specific toxicity rate across time:

$$DCPA = \int k_{tox} [C(x, t), T(x, t), \text{tissue}] dt$$

The function k_{tox} is empirical and must be measured for the target tissue. The concept prevents a misleading optimization in which rapid physical processing at one stage lengthens a more toxic exposure at another. Combined with transport modeling, the ledger can identify whether faster loading, lower temperature, alternative formulation, or faster washout produces the largest reduction in injury.

7. Organ specific translation cannot be skipped

Table 3. Organ specific bottlenecks and decisive next tests.

Organ or tissue	Dominant translation risk	Decisive next experiment
Kidney	Tubular cryoprotectant injury, regional particle retention, and scale from rat to clinically relevant graft.	Paired large animal transplantation with survival dependent renal function and prespecified OBM thresholds.
Heart	Coronary distribution, electrical recovery, contractility, and fracture at a much larger scale.	Large animal orthotopic transplant with pressure, output, rhythm, and coronary microvascular endpoints.
Liver	Dual inflow, biliary underprotection, high volume, and heterogeneous parenchymal transport.	Dual route loading, biliary protection, nanowarming of a human scale liver, then transplant function.
Lung	Air tissue interfaces, edema, fragile capillaries, low tolerance for obstruction, and complex geometry.	Controlled inflation plus vascular particle loading, gas exchange after nanowarming, and transplant validation.
Pancreas	Exocrine enzyme injury, ductal integrity, edema, and microvascular heterogeneity.	Endocrine and exocrine function after large animal recovery, followed by transplantation.
Cartilage and composite grafts	Avascular or poorly vascularized regions cannot receive a uniform intravascular heat source.	Hybrid surrounding and targeted bone side heating with depth resolved viability and mechanics.

The kidney is currently the lead organ because it has a single arterial inflow, favorable vascular access, and a clear survival dependent endpoint. The liver is more challenging because a portal only protocol does not reproduce dual inflow and may leave the biliary tree vulnerable. The heart adds an uncompromising demand for organized electrical and mechanical function. The lung may be hardest because its air tissue interfaces and extensive delicate capillary bed complicate particle loading, heat transfer, edema control, and washout. A universal nanowarming recipe is unlikely. The platform can be shared, but the perfusion, chemistry, control law, and acceptance tests must be organ specific.

8. A staged experimental program toward clinical organ banking

8.1 Stage one, define the complete physical envelope

1. Measure critical cooling and warming rates in actual target tissue at the achieved local cryoprotectant concentration, not only in bulk solution.
2. Map cryoprotectant and nanoparticle distribution in three dimensions before vitrification, with explicit sensitivity and spatial resolution.
3. Validate cooling, annealing, storage, and warming models against multipoint thermometry and ice sensitive imaging.
4. Calculate local stress and compare it with measured fracture limits for the organ, container, and cryoprotective formulation.

8.2 Stage two, establish biological causality

5. Use factorial controls that separate loading toxicity, cooling injury, storage injury, warming injury, particle exposure, and washout injury.
6. Perform blinded histopathology and organ specific normothermic perfusion with predefined failure rules.
7. Test whether injury colocalizes with the lowest particle concentration, lowest warming margin, highest stress, or greatest residual burden.
8. Repeat protocols across donor age, sex, warm ischemia, vascular disease, and marginal graft conditions rather than healthy young organs alone.

8.3 Stage three, demand large animal transplantation

The next decisive step is not a larger cryoprotective bag. It is a large animal organ that is loaded, vitrified, banked, nanowarmed, unloaded, transplanted, and shown to support life or organ specific function for a clinically meaningful interval. Randomization, blinded outcome assessment, transparent exclusions, and comparison with optimized cold storage or machine perfusion are essential. Storage duration should be varied independently from the thermal protocol to determine whether long term glass aging changes recovery.

8.4 Stage four, build a regulated manufacturing and release system

Clinical translation requires controlled nanoparticle synthesis, purification, sterility, endotoxin testing, lot specific heating calibration, cryoprotective agent quality, closed perfusion circuits, validated sensors, traceable software, and a release assay that can be completed before transplantation. Tangential flow filtration and clinically familiar iron oxide formulations are meaningful advances, but neither removes the need for product specific quality control (Oziri et al., 2025; Feng et al., 2026). The release decision should combine the Organ Banking Margin with biological perfusion data, not use either alone.

9. Testable predictions

A useful perspective should risk being wrong. The following predictions distinguish the framework proposed here from a simple scale up narrative.

- **Spatial prediction.** Postwarming injury will correlate more strongly with the lowest decile of local nanoparticle concentration and warming margin than with mean organ iron or mean warming rate.
- **Compensation prediction.** At equal total iron mass, a model designed nonuniform particle distribution will reduce maximum thermal gradient and improve minimum warming margin compared with uniform loading.
- **Causality prediction.** Once local warming and stress margins exceed 1 throughout the organ, additional RF power will yield little biological improvement unless cryoprotectant dose and washout are improved.
- **Storage prediction.** Under stable storage sufficiently below the glass transition, functional outcome will be substantially less sensitive to duration than to temperature excursions and passage through the crystallization danger interval. Very long storage may still alter the glass and required warming rate, so the prediction is conditional, not absolute.
- **Imaging prediction.** A three dimensional prewarming nanoparticle map combined with a validated digital twin will predict damaged regions better than sparse temperature probes alone.
- **Formulation prediction.** Additives that lower critical warming rate will not automatically improve organ outcome, because some will destabilize particles, change dielectric loss, slow diffusion, or increase tissue specific toxicity. Joint formulation optimization will outperform sequential optimization.
- **Organ prediction.** Biliary injury will remain the limiting lesion in liver nanowarming until hepatic arterial and biliary protection are explicitly engineered, even when parenchymal temperature control appears successful.
- **Translation prediction.** Ferumoxytol will shorten nanoparticle chemistry development but will not eliminate the need for organ specific residual limits, spatial dosimetry, and transplant validation.

10. Alternatives and combinations

Nanowarming should not be evaluated against a false choice between magnetic heating and conventional surface warming. Dielectric warming at tens of megahertz has produced renewed evidence for rapid organ rewarming, and focused ultrasound, microwave systems, and hybrid methods remain active research areas (Wowk et al., 2024; Wowk, 2026). Each method has a different distribution of penetration, coupling, thermal runaway, geometric sensitivity, and hardware complexity. The scientifically strongest program will compare them under the same cryoprotective formulation, organ geometry, thermal metrics, and biological endpoints.

Hybridization may be especially useful. Convective cooling can be combined with careful annealing. Nanowarming could be supplemented by controlled boundary heating to compensate for surface losses. Dielectric energy might assist a temperature interval in which particle SAR falls, provided electric field heating remains uniform. Machine perfusion is not a competitor to banking, but the recovery and qualification stage after washout. The future organ bank is likely to be a chain of technologies rather than a single device.

11. Limitations of the present evidence

The strongest transplant experiment remains a five animal syngeneic rat kidney series with 30 days of followup. Rat organs are orders of magnitude smaller than human organs, and healthy syngeneic recipients do not model immunosuppression, alloimmunity, vascular disease, donor age, prolonged warm ischemia, or marginal grafts. Human scale studies have established physical feasibility in cryoprotective agent volumes and vitrified porcine liver, but no human scale organ has yet completed the full chain of vitrification, long duration storage, nanowarming, washout, transplantation, and durable function.

Temperature is measured at limited locations, particle assays vary in spatial resolution, and absence of visible ice or cracking does not exclude microscopic injury. Critical rates depend on tissue, concentration, thermal history, and nucleation burden. Toxicology data are encouraging but remain species specific and do not fully model residual particles within a transplanted graft. The proposed weakest voxel principle, Organ Banking Margin, particle gradient compensation, and thermal dose ledger are hypotheses and engineering constructs. They require prospective validation and should not be presented as clinical release standards until validated.

12. Conclusion

Nanowarming has moved organ banking from a speculative idea to a credible translational program. The field has already demonstrated the essential chain in miniature: vascular nanoparticle delivery, ice free vitrification, rapid and uniform magnetic rewarming, particle and cryoprotectant washout, organ recovery, and survival dependent transplantation. It has also demonstrated the relevant physics at the liter scale. The remaining question is no longer whether magnetic nanoparticles can warm an organ sized volume. The question is whether every critical region of a human scale organ can be protected, warmed, cleared, and returned to durable function with a reproducible manufacturing and control system.

The answer will not come from chasing a single record warming rate. It will come from controlling the weakest voxel, measuring every margin, matching chemistry to anatomy, and refusing to call physical success biological success. A closed loop platform that combines molecular cryoprotectant design, imageable magnetic nanoparticles, organ specific perfusion, digital twin control, and transplant level validation offers the clearest route forward. If those components are solved together, organ transplantation could shift from emergency logistics to planned medicine, and donated organs could become banked biological resources rather than expiring opportunities.

References

- Chen, P., Wang, S., Chen, Z., et al. (2023). Nanowarming and ice free cryopreservation of large sized, intact porcine articular cartilage. *Communications Biology*, 6, 220. <https://doi.org/10.1038/s42003-023-04577-9>
- Chiu Lam, A., Staples, E., Pepine, C. J., and Rinaldi, C. (2021). Perfusion, cryopreservation, and nanowarming of whole hearts using colloiddally stable magnetic cryopreservation agent solutions. *Science Advances*, 7, eabe3005. <https://doi.org/10.1126/sciadv.abe3005>
- de Vries, R. J., Tessier, S. N., Banik, P. D., et al. (2019). Supercooling extends preservation time of human livers. *Nature Biotechnology*, 37, 1131 to 1136. <https://doi.org/10.1038/s41587-019-0223-y>
- Fahy, G. M., MacFarlane, D. R., Angell, C. A., and Meryman, H. T. (1984). Vitrification as an approach to cryopreservation. *Cryobiology*, 21, 407 to 426. <https://pubmed.ncbi.nlm.nih.gov/6467964/>
- Fahy, G. M., Wowk, B., Wu, J., and Paynter, S. (2004). Improved vitrification solutions based on predictability of vitrification solution toxicity. *Cryobiology*, 48, 22 to 35. <https://pubmed.ncbi.nlm.nih.gov/14969680/>
- Feng, H., Mao, Y., Zhang, Y., et al. (2026). Repurposing ferumoxytol as a nanowarming agent for vitrification based organ preservation. *Nano Today*, 67, 102981. <https://doi.org/10.1016/j.nantod.2026.102981>
- Gangwar, L., Han, Z., Scheithauer, C., et al. (2025a). Physical vitrification and nanowarming at liter scale cryoprotective agent volumes, toward organ cryopreservation. *Nature Communications*, 16, 8511. <https://doi.org/10.1038/s41467-025-63483-2>
- Gangwar, L., et al. (2025b). Dielectric properties of individual cryoprotective agents and cocktails VS55, M22, and DP6 at subzero temperatures for cryopreservation. *Scientific Reports*, 15, 20734. <https://doi.org/10.1038/s41598-025-07207-y>
- Gao, Z., Ring, H. L., Sharma, A., et al. (2020). Preparation of scalable silica coated iron oxide nanoparticles for nanowarming. *Advanced Science*, 7, 1901624. <https://doi.org/10.1002/advs.201901624>
- Gao, Z., Namsrai, B., Han, Z., et al. (2022). Vitrification and rewarming of magnetic nanoparticle loaded rat hearts. *Advanced Materials Technologies*, 7, 2100873. <https://doi.org/10.1002/admt.202100873>
- Giwa, S., Lewis, J. K., Alvarez, L., et al. (2017). The promise of organ and tissue preservation to transform medicine. *Nature Biotechnology*, 35, 530 to 542. <https://doi.org/10.1038/nbt.3889>
- Guan, N., Blomsma, S. A., van Midwoud, P., et al. (2012). Effects of cryoprotectant addition and washout methods on the viability of precision cut liver slices. *Cryobiology*, 65, 179 to 187. <https://pubmed.ncbi.nlm.nih.gov/22722061/>
- Han, Z., Rao, J. S., Gangwar, L., et al. (2023a). Vitrification and nanowarming enable long term organ cryopreservation and life sustaining kidney transplantation in a rat model. *Nature Communications*, 14, 3407. <https://doi.org/10.1038/s41467-023-38824-8>
- Han, Z., et al. (2023b). Model guided design and optimization of cryoprotective agent perfusion protocols for whole organ cryopreservation. *Annals of Biomedical Engineering*, 51, 2216 to 2228. <https://doi.org/10.1007/s10439-023-03255-5>
- Joshi, P., Ehrlich, L. E., Gao, Z., Bischof, J. C., and Rabin, Y. (2022). Thermal analyses of nanowarming assisted recovery of the heart from cryopreservation by vitrification. *Journal of Heat Transfer*, 144, 031202. <https://doi.org/10.1115/1.4053105>
- Joshi, P., et al. (2023). Thermomechanical stress analyses of nanowarming assisted recovery from cryopreservation by vitrification in human heart and rat heart models. *PLOS ONE*, 18, e0290063. <https://doi.org/10.1371/journal.pone.0290063>
- Kantesaria, S. A., Tang, X., Suddarth, S., et al. (2024). A low cost, tabletop longitudinal detection electron paramagnetic resonance system for nondestructive quantification of iron oxide nanoparticles in tissues. *ACS Sensors*, 9, 262 to 271. <https://doi.org/10.1021/acssensors.3c01898>
- Lewis, J. K., Bischof, J. C., Braslavsky, I., et al. (2016). The grand challenges of organ banking, proceedings from the first global summit on complex tissue cryopreservation. *Cryobiology*, 72, 169 to 182. <https://doi.org/10.1016/j.cryobiol.2015.12.001>
- Manuchehrabadi, N., Gao, Z., Zhang, J., et al. (2017). Improved tissue cryopreservation using inductive heating of magnetic nanoparticles. *Science Translational Medicine*, 9, eaah4586. <https://doi.org/10.1126/scitranslmed.aah4586>
- Murray, K. A., and Gibson, M. I. (2022). Chemical approaches to cryopreservation. *Nature Reviews Chemistry*, 6, 579 to 593. <https://doi.org/10.1038/s41570-022-00407-4>

- Oziri, O. J., Rao, J. S., Scheithauer, C., et al. (2025). Scalable purification of iron oxide nanoparticles for organ cryopreservation and transplantation. *Small*, 21, e04910. <https://doi.org/10.1002/sml.202504910>
- Oziri, O. J., Scheithauer, C., Wong, H. L., et al. (2026). In vivo toxicity assessment of silica coated iron oxide nanoparticles for nanowarming in organ cryopreservation. *Journal of Nanobiotechnology*, 24, 603. <https://doi.org/10.1186/s12951-026-04471-6>
- Rabin, Y., Steif, P. S., Hess, K. C., Jimenez Rios, J. L., and Palastro, M. C. (2006). Fracture formation in vitrified thin films of cryoprotectants. *Cryobiology*, 53, 75 to 95. <https://pubmed.ncbi.nlm.nih.gov/16765938/>
- Sharma, A., Rao, J. S., Han, Z., et al. (2021). Vitrification and nanowarming of kidneys. *Advanced Science*, 8, 2101691. <https://doi.org/10.1002/advs.202101691>
- Sharma, A., Lee, C. Y., Namsrai, B. E., et al. (2023). Cryopreservation of whole rat livers by vitrification and nanowarming. *Annals of Biomedical Engineering*, 51, 566 to 577. <https://doi.org/10.1007/s10439-022-03064-2>
- Tessier, S. N., de Vries, R. J., Pendexter, C. A., et al. (2022). Partial freezing of rat livers extends preservation time by five fold. *Nature Communications*, 13, 4008. <https://doi.org/10.1038/s41467-022-31490-2>
- Warren, M. T., et al. (2024). Data driven discovery of potent small molecule ice recrystallisation inhibitors. *Nature Communications*, 15, 8082. <https://doi.org/10.1038/s41467-024-52266-w>
- Wowk, B., Phan, J., Pagotan, R., Galvez, E., and Fahy, G. M. (2024). 27 megahertz constant field dielectric warming of kidneys cryopreserved by vitrification. *Cryobiology*, 115, 104893. <https://doi.org/10.1016/j.cryobiol.2024.104893>
- Wowk, B. (2026). Electric fields for warming cryopreserved tissue. *Cryobiology*, 123, 105627. <https://doi.org/10.1016/j.cryobiol.2026.105627>
- Ye, Z., Tai, Y., Han, Z., et al. (2024). Engineering magnetic nanoclusters for highly efficient heating in radiofrequency nanowarming. *Nano Letters*, 24, 4588 to 4594. <https://doi.org/10.1021/acs.nanolett.4c00721>